HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.
February 13, 2012 TUCSON, Ariz. — HTG Molecular , a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans , Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer,
HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine TUCSON, Ariz.
TUCSON, Ariz. (April 26, 2012) – HTG Molecular Diagnostics, a privately-held, Tucson-based provider of molecular-technology solutions, hired Chris Roberts as vice president of medical innovation. Roberts joins HTG from Caris Life Sciences where he served as vice president of the oncology division
TUCSON, Ariz. (May 14, 2012) – Sam Rua, vice president of regulatory affairs and quality systems at HTG Molecular Diagnostics, will offer a keynote presentation, “Update on Commercialization of RUO and IUO Products and Oversight of Lab-Developed Tests,” at the 2012 TIDES Oligonucleotide and Peptide
TUCSON, Ariz. (June 1, 2012) – The John Wayne Cancer Institute (JWCI) at Saint John’s Health Center in Santa Monica, California selected HTG Molecular Diagnostics as an exclusive commercialization partner for recently identified HTG melanoma signature assays which may be useful for diagnostic and